(Press-News.org) LONDON, UK - 30 August, 2015: Heart attack patients without heart failure derive no benefit from the addition of mineralocortoid receptor antagonists (MRA), to standard therapy, results of the ALBATROSS study show.
The Hot Line findings, reported at ESC Congress 2015, "do not warrant the extension of MRA use" to such patients, said the study's principal investigator Gilles Montalescot, MD, PhD.
MRAs, also known as aldosterone antagonists, inhibit sodium retention and excretion of potassium and magnesium, and therefore "there is an indication for MRA therapy in MI patients with heart failure," explained Professor Montalescot, from the Institut de Cardiologie, Centre Hospitalier Universitaire Pitié-Salpêtri?re, in Paris, France.
"Our results suggest that heart failure is the main factor for the favorable effect of MRAs previously observed in MI patients. In MI patients without heart failure we observed no benefit. We suggest to respect the current indication driven by heart failure."
But there is a silver lining to the ALBATROSS findings, which do suggest "a potential mortality benefit" of MRA treatment among a specific group of patients who have ST-segment elevation myocardial infarction (STEMI), although this result "must be interpreted with great caution," warned Professor Montalescot.
"It is an intriguing, hypothesis-generating finding which needs to be examined further in adequately-sized trials specifically dedicated to STEMI patients," he said.
While the MRAs spironolactone and eplerenone have both been shown to reduce mortality in heart attack patients with congestive heart failure, very little is known about this treatment in the absence of heart failure - the more common scenario among patients who are hospitalised for myocardial infarction (MI).
Therefore, ALBATROSS (which stands for Aldosterone Lethal effects Blockade in Acute myocardial infarction Treated with or without Reperfusion to improve Outcome and Survival at Six months follow-up) investigated the effects of prolonged MRA therapy initiated early after the onset of MI in a broad population, 92% of whom presented without heart failure.
The study included 1622 patients randomly assigned to standard therapy alone (n=801) or with the addition of MRA therapy (n=802).
The randomisation took place as early as possible, including in ambulances, to allow for early treatment.
Standard therapy included in-hospital medications as well as procedures such as coronary angiography, percutaneous coronary intervention and coronary bypass grafting.
The MRA regimen consisted of an intravenous bolus of potassium canrenoate (200 mg) followed by an initial 25mg of oral spironolactone within 12 to 24 hours, and then daily for 6 months. Spironolactone was not given if either potassium or creatinine concentrations were uncontrolled (> 5* 5 mmol.L-1 and >220 µmol.L-1 respectively).
After a median follow-up of 118 days, the primary outcome - a composite of death, resuscitated cardiac arrest, significant ventricular arrhythmia, indication for an implantable defibrillator or new or worsening heart failure at 6-months - occurred at a similar rate in the treatment and control groups (11* 8% and 12* 2% respectively, hazard ratio [HR] 0* 97).
However, for the outcome of mortality alone, MRA reduced the odds of death in the subgroup of STEMI (n=1229, HR 0* 20, 95% CI, 0.06 to 0.70), but not NSTEMI patients.
Caution in interpreting this finding is warranted since the study was not designed to specifically assess STEMI patients, said Professor Montalescot, but he added that a potential benefit of early MR therapy is plausible in STEMI patients, who are "a more homogeneous patient population with more acute and severe myocardial ischemia than NSTEMI".
The ALBATROSS study, which is the largest study of MRA therapy in MI patients without heart failure, also highlights the relative safety of the MRA regimen used. Adverse events were equally distributed between the two study groups and although rates of hyperkalemia (high plasma potassium) were more common in the MRA group than in the control group, they were lower than what has been previously reported, he concluded.
INFORMATION:
LONDON, UK - In patients with a large myocardical infarction (MI), pacing, with the left ventricular (LV) lead placed in the area of the lesion (peri-infarct) did not prevent further enlargement of the heart (remodeling), nor did it improve functional or clinical outcomes after 18 months, according to results of the Pacing Remodeling Prevention Therapy trial (PRomPT) trial.
In MI patients with large infarcts, medical therapy and rapid restoration of blood flow to the area is not always enough to prevent cardiac remodeling.
One reason for remodeling may be the response ...
LONDON, UK - 30 August, 2015: The immunosuppressant drug cyclosporine did not improve clinical outcomes compared to placebo in patients receiving percutaneous coronary intervention (PCI) for the more severe form of heart attack known as ST-segment elevation myocardial infarction (STEMI).
Results of the CIRCUS trial, presented today in a Hot Line session at ESC Congress 2015, and published simultaneously in the New England Journal of Medicine. showed that the drug, administered prior to PCI, had no impact on a composite of all-cause death, hospitalisation for - or worsening ...
LONDON, UK - In patients with chronic ischemic heart disease, a small left ventricle with thick walls, is the strongest predictor of morphologic remodelling, which is generally considered a first step towards heart failure, according to unexpected findings presented today at ESC Congress 2015.
Results of the DOPPLER-CIP (which stands for "Determining Optimal non-invasive Parameters for the Prediction of Left vEntricular morphologic and functional Remodeling in Chronic Ischemic Patients") study were not expected and, if confirmed by other studies, "could completely change ...
A major multi-national study of suicides has identified the behaviour patterns which precede many suicide attempts. This may lead to changes in clinical practice in the care of patients affected with depression, as it shows the clinical factors which confer major risk of suicide attempts.
The statistics for suicide are frightening. According to the WHO, more than 800,000 people commit suicide every year, with perhaps 20 times that number attempting suicide. Suicide is one of the leading causes of death in the young (in the UK for example, it is the leading cause of death ...
A group of UK scientists have found a way of understanding how transcranial magnetic stimulation (TMS) can give relief to severely depressed patients. TMS is used as an alternative to Electro-Convulsive Therapy (ECT)*, but it is not known how it achieves its therapeutic effect. Understanding how it works may open the door to better, more targeted treatment for depression and other conditions.
Transcranial magnetic stimulation works by applying a magnetic pulse to the frontal part of the brain of depressed patients. Like ECT, it seems to 'reset' the brain, but is easier ...
A single dose of cocaine can interfere with the ability to recognise negative emotions, according to new research presented at the ECNP conference in Amsterdam.
In a placebo-controlled within subject study, researchers from the Netherlands and Germany took 24 students (aged 19 to 27) with light to moderate cocaine use, and gave them either 300mg of oral cocaine, or a placebo.
After 1 to 2 hours, each participant was then subject to a series of biochemical tests, as well as the facial emotion recognition test to measure response to a series of basic emotions, such ...
London, UK - 29 Aug 2015: Depressive symptoms and extremes of blood pressure predict the highest rates of harmful vascular events in patients with existing heart disease, diabetes or stroke, according to research presented at ESC Congress today by Dr Bhautesh Jani, clinical academic fellow in the Institute of Health and Wellbeing, University of Glasgow, UK.1
The study in more than 35 000 patients found that the risk of further stroke or heart attack, heart failure or dying due to heart disease at four years was 83% higher in depressed patients with high blood pressure ...
London, UK - 29 Aug 2015: Prolonged television watchers have a higher risk of fatal pulmonary embolism, a condition associated with long haul flights, reveals research presented at ESC Congress today by Mr Toru Shirakawa, public health research fellow in the Department of Social Medicine at Osaka University in Japan.1 The 18 year study in more than 86 000 people found that watching an average of five or more hours of television per day was associated with twice the risk of fatal pulmonary embolism as watching less than two and a half hours daily.
"The association between ...
London, UK - 29 Aug 2015: Midday naps are associated with reduced blood pressure levels and prescription of fewer antihypertensive medications, according to research presented at ESC Congress today by Dr Manolis Kallistratos, a cardiologist at Asklepieion Voula General Hospital in Athens, Greece.1
"Although William Blake affirms that it is better to think in the morning, act at noon, eat in the evening and sleep at night, noon sleep seems to have beneficial effects," said Dr Kallistratos. "Two influential UK Prime Ministers were supporters of the midday nap. Winston Churchill ...
London, UK - 29 Aug 2015: Coffee drinking is associated with increased risk of cardiovascular events (mainly heart attacks) in young adults (18-45) with mild hypertension, according to research presented at ESC Congress today by Dr Lucio Mos, a cardiologist at Hospital of San Daniele del Friuli in Udine, Italy.1 The 12 year study in more than 1 200 patients found that heavy coffee drinkers had a four-fold increased risk while moderate drinkers tripled their risk. Future prediabetes attenuated the associations suggesting that the effect of coffee on cardiovascular events ...
